Saniona (SANION) Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SANION Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.72 |
| 52 Week High | SEK 28.30 |
| 52 Week Low | SEK 5.41 |
| Beta | 1.23 |
| 1 Month Change | 2.45% |
| 3 Month Change | -21.13% |
| 1 Year Change | 170.11% |
| 3 Year Change | 133.19% |
| 5 Year Change | -27.30% |
| Change since IPO | 224.66% |
Recent News & Updates
Recent updates
There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 35% Share Price Rise
Dec 23
There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 32% Share Price Rise
Oct 19Saniona AB (publ) (STO:SANION) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Aug 21Improved Revenues Required Before Saniona AB (publ) (STO:SANION) Stock's 37% Jump Looks Justified
Jun 19Increases to Saniona AB (publ)'s (STO:SANION) CEO Compensation Might Cool off for now
May 22Saniona AB (publ)'s (STO:SANION) 28% Dip In Price Shows Sentiment Is Matching Revenues
Mar 13Is Saniona (STO:SANION) Using Debt Sensibly?
Nov 06Is Saniona (STO:SANION) Weighed On By Its Debt Load?
Jul 30Saniona (STO:SANION) Is Making Moderate Use Of Debt
Nov 29Is Saniona (STO:SANION) Using Too Much Debt?
Aug 16Is Saniona (STO:SANION) Using Too Much Debt?
Mar 17Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares
Feb 10What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?
Jan 06Is Saniona (STO:SANION) Using Too Much Debt?
Dec 02Shareholder Returns
| SANION | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 4.0% | 6.3% | 2.7% |
| 1Y | 170.1% | 19.9% | 9.4% |
Return vs Industry: SANION exceeded the Swedish Biotechs industry which returned 14.1% over the past year.
Return vs Market: SANION exceeded the Swedish Market which returned 5.7% over the past year.
Price Volatility
| SANION volatility | |
|---|---|
| SANION Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: SANION's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SANION's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 34 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder.
Saniona AB (publ) Fundamentals Summary
| SANION fundamental statistics | |
|---|---|
| Market cap | SEK 2.31b |
| Earnings (TTM) | SEK 284.67m |
| Revenue (TTM) | SEK 434.40m |
Is SANION overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANION income statement (TTM) | |
|---|---|
| Revenue | SEK 434.40m |
| Cost of Revenue | SEK 5.43m |
| Gross Profit | SEK 428.97m |
| Other Expenses | SEK 144.30m |
| Earnings | SEK 284.67m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 27, 2026
| Earnings per share (EPS) | 2.06 |
| Gross Margin | 98.75% |
| Net Profit Margin | 65.53% |
| Debt/Equity Ratio | 0% |
How did SANION perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 00:58 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Saniona AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Novod | Nordea Markets |
| Jesper Ilsoe | Nordea Markets |
| Fredrik Thor | Redeye |